# EDGAR Filing Document

**Accession Number:** 0001770787
**File Stem:** 0001628280-26-007673
**Filing Date:** 2026-2
**Character Count:** 21355
**Document Hash:** 1a44979b06521e496d8830d02d9bcd71
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-007673.hdr.sgml**: 20260212

**ACCESSION NUMBER**: 0001628280-26-007673

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20260212

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260212

**DATE AS OF CHANGE**: 20260212

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** 10x Genomics, Inc.
- **CENTRAL INDEX KEY:** 0001770787
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 455614458
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39035
- **FILM NUMBER:** 26626266

**BUSINESS ADDRESS:**
- **STREET 1:** 6230 STONERIDGE MALL ROAD
- **CITY:** PLEASANTON
- **STATE:** CA
- **ZIP:** 94588
- **BUSINESS PHONE:** (925) 401-7300

**MAIL ADDRESS:**
- **STREET 1:** 6230 STONERIDGE MALL ROAD
- **CITY:** PLEASANTON
- **STATE:** CA
- **ZIP:** 94588

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 10X Genomics, Inc.
- **DATE OF NAME CHANGE:** 20190315

?xml version='1.0' encoding='ASCII'? txg-20260212

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**______________________**

**FORM 8-K**

**______________________**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 12, 2026**

![Logo-10x.jpg](txg-20260212_g1.jpg)

**10x Genomics, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39035** | **45-5614458** |
| **(State or other jurisdiction**<br>**of incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

**6230 Stoneridge Mall Road**

**Pleasanton, California 94588**

**(925) 401-7300**

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)**

**___________________________**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol** | **Name of each exchange**<br>**on which registered** |
| **Class A common stock, par value $0.00001 per share** | **TXG** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition.**

On February 12, 2026, 10x Genomics, Inc. (the "Company") issued a press release announcing the Company's financial results for the fourth quarter and full year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

The information furnished pursuant to Item 2.02 in this Current Report on Form 8-K and the press release attached as Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;(d)*Exhibits.*

---

| | |
|:---|:---|
| Exhibit No. | Description of Exhibits |
| 99.1 | <u>[Press Release dated February 12, 202](txg-fy2025earningsreleasee.htm)[6](txg-fy2025earningsreleasee.htm)[.](txg-fy2025earningsreleasee.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | 10x Genomics, Inc. | 10x Genomics, Inc. |
| | | By: | /s/ Randy Wu |
| | | Name: | Randy Wu |
| | | Title: | General Counsel and Secretary |
| Date: | February 12, 2026 |  |  |

---

## Exhibit 99.1

**Exhibit 99.1**

![a10x_logoxhorizontalxfullca.jpg](a10x_logoxhorizontalxfullca.jpg)

**10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026**

**PLEASANTON, Calif.** February 12, 2026 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided its outlook for 2026.

**Recent Updates**

&nbsp;&nbsp;&nbsp;&nbsp;• Revenue was $166.0 million for the fourth quarter of 2025, representing a 1% increase over the corresponding period of 2024. Revenue was $642.8 million for the full year of 2025. Excluding $44.1 million of non-recurring revenue related to patent litigation settlements, full-year revenue was $598.7 million, representing a 2% decrease from the full year of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;• Announced partnerships with the Cancer Research Institute and PharosAI to build some of the world's largest AI-ready datasets for cancer research, leveraging our Chromium and Xenium platforms to transform thousands of clinical samples into high-resolution multimodal insights for drug discovery and diagnostics.

&nbsp;&nbsp;&nbsp;&nbsp;• Entered into a collaboration with Dana-Farber Cancer Institute to analyze patient tumor samples, marking the beginning of a multi-year research initiative to incorporate single cell and spatial tumor analysis into potential diagnostic workflows to support cancer patient care.

&nbsp;&nbsp;&nbsp;&nbsp;• Launched a study with Brigham & Women's Hospital aimed at identifying single cell blood-based signatures of autoimmune disease activity and treatment response to support clinical care.

&nbsp;&nbsp;&nbsp;&nbsp;• Ended the year with $523.4 million of cash and cash equivalents and marketable securities, an increase of $130.0 million over the prior year.

"In 2025, our team executed with discipline through a challenging environment while continuing to strengthen the fundamentals of the business," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "As we look to 2026, I am excited by the expanding impact of our platforms, driven by new product innovations and strategic partnerships. We are well positioned to execute across multiple growth vectors in the business, especially AI-driven demand, translational research and emerging clinical opportunities."

**Fourth Quarter 2025 Financial Results**

Revenue was $166.0 million for the three months ended December 31, 2025, a 1% increase from $165.0 million for the corresponding prior year period.

Gross margin was 68% for the fourth quarter of 2025, as compared to 67% for the corresponding prior year period. The increase in gross margin was primarily due to lower inventory write-downs, lower royalty costs and lower warranty costs, partially offset by higher manufacturing costs.

Operating expenses were $132.6 million for the fourth quarter of 2025, an 18% decrease from $160.8 million for the corresponding prior year period. The decrease was primarily driven by lower outside legal expenses and personnel expenses.

Operating loss was $19.5 million for the fourth quarter of 2025, as compared to an operating loss of $49.8 million for the corresponding prior year period. This includes $25.2 million of stock-based compensation for the fourth quarter of 2025, as compared to $32.5 million for the fourth quarter of 2024.

Net loss was $16.3 million for the fourth quarter of 2025, as compared to a net loss of $49.0 million for the corresponding prior year period.

**Full Year 2025 Financial Results** 

Revenue was $642.8 million for the year ended December 31, 2025, a 5% increase from $610.8 million for 2024. Excluding $44.1 million related to patent litigation settlements, full-year revenue was $598.7 million, a 2% decrease from the prior year.

------

![a10x_logoxhorizontalxfullca.jpg](a10x_logoxhorizontalxfullca.jpg)

Gross margin was 69% for full year 2025, as compared to 68% for 2024. The increase in gross margin was primarily due to higher license and royalty revenue and lower royalties and warranty costs, partially offset by an increase in inventory write-downs and higher manufacturing costs.

Operating expenses were $504.9 million for full year 2025, as compared to $609.0 million for 2024, a decrease of 17%. The decrease was primarily driven by a $49.9 million gain on litigation settlements, lower outside legal expenses and personnel expenses.

Operating loss was $61.0 million for full year 2025, as compared to an operating loss of $194.6 million for 2024. This includes $108.8 million of stock-based compensation for full year 2025, as compared to $140.7 million for full year 2024.

Net loss was $43.5 million for full year 2025, as compared to a net loss of $182.6 million for 2024.

Cash and cash equivalents and marketable securities were $523.4 million as of December 31, 2025.

**2026 Financial Guidance** 

10x Genomics expects full year 2026 revenue to be in the range of $600 million to $625 million. Excluding the non-recurring license and royalty revenue related to patent litigation settlements in 2025, this represents 0% to 4% growth over full year 2025.

**Webcast and Conference Call Information**

10x Genomics will host a conference call to discuss the fourth quarter and full year 2025 financial results, business developments and outlook after market close on Thursday, February 12, 2026 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the conference call can be accessed at <u>http://investors.10xgenomics.com</u>. The webcast will be archived and available for replay for at least 45 days after the event.

**About 10x Genomics**

10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit <u>10xgenomics.com</u> or connect with us on <u>LinkedIn</u>, <u>X</u>, <u>Facebook</u>, <u>Bluesky</u> or <u>YouTube</u>.

**Forward Looking Statements**

------

![a10x_logoxhorizontalxfullca.jpg](a10x_logoxhorizontalxfullca.jpg)

company's most recently-filed 10-K and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.

**Disclosure Information**

10x Genomics uses filings with the Securities and Exchange Commission, our website (<u>www.10xgenomics.com</u>), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

**Contacts**

Investors: <u>investors@10xgenomics.com</u>

Media: <u>media@10xgenomics.com</u>

------

![a10x_logoxhorizontalxfullca.jpg](a10x_logoxhorizontalxfullca.jpg)

**10x Genomics, Inc.**

**Consolidated Statement of Operations**

*(Unaudited)*

*(In thousands, except share and per share data)*

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| Products and services revenue | $165689 | $164910 | $596688 | $610464 |
| License and royalty revenue | 341 | 111 | 46135 | 321 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenue <sup>(1)</sup> | 166030 | 165021 | $642823 | $610785 |
| Cost of products and services revenue <sup>(2)</sup> | 52985 | 54066 | 198942 | 196303 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 113045 | 110955 | 443881 | 414482 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development <sup>(2)</sup> | 55969 | 66968 | 238632 | 264698 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative <sup>(2)</sup> | 76617 | 93826 | 316134 | 344343 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on settlement |  |  | (49900) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 132586 | 160794 | 504866 | 609041 |
| Loss from operations | (19541) | (49839) | (60985) | (194559) |
| Other income (expense): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income | 5492 | 4467 | 20048 | 18930 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense |  |  |  | (4) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other (expense) income, net | (1144) | (3008) | 1030 | (2067) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other income | 4348 | 1459 | 21078 | 16859 |
| Loss before provision for income taxes | (15193) | (48380) | (39907) | (177700) |
| Provision for income taxes | 1059 | 648 | 3637 | 4927 |
| Net loss | $(16252) | $(49028) | $(43544) | $(182627) |
| Net loss per share, basic and diluted | $(0.13) | $(0.40) | $(0.35) | $(1.52) |
| Weighted-average shares used to compute net loss per share, basic and diluted | 127078342 | 121596351 | 124749885 | 120451550 |

---

(1)The following table represents revenue by source for the periods indicated (in thousands). Spatial products includes the Company's Visium and Xenium products:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Instruments** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Single Cell | $6105 | $10929 | $22671 | $35212 |
| &nbsp;&nbsp;&nbsp;&nbsp;Spatial | 9364 | 13425 | 34108 | 57503 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total instruments revenue** | 15469 | 24354 | 56779 | 92715 |
| **Consumables** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Single Cell | 100790 | 97737 | 363206 | 372308 |
| &nbsp;&nbsp;&nbsp;&nbsp;Spatial | 40959 | 35795 | 143977 | 121124 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total consumables revenue** | 141749 | 133532 | 507183 | 493432 |
| **Services** | 8471 | 7024 | 32726 | 24317 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Products and services revenue** | 165689 | 164910 | 596688 | 610464 |
| **License and royalty revenue** | 341 | 111 | 46135 | 321 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total revenue** | $166030 | $165021 | $642823 | $610785 |

---

------

![a10x_logoxhorizontalxfullca.jpg](a10x_logoxhorizontalxfullca.jpg)

The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Americas** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;United States | $78957 | $84285 | $346512 | $334318 |
| &nbsp;&nbsp;&nbsp;&nbsp;Americas (excluding United States) | 3217 | 2936 | 12261 | 13447 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Americas** | 82174 | 87221 | 358773 | 347765 |
| **Europe, Middle East and Africa** | 53463 | 49828 | 161716 | 159762 |
| **Asia-Pacific** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;China | 15022 | 14609 | 70264 | 57300 |
| &nbsp;&nbsp;&nbsp;&nbsp;Asia-Pacific (excluding China) | 15371 | 13363 | 52070 | 45958 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Asia-Pacific** | 30393 | 27972 | 122334 | 103258 |
| Total Revenue | $166030 | $165021 | $642823 | $610785 |

---

(2)Includes stock-based compensation expense as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** |
| **(in thousands)** | **2025** | **2024** | **2025** | **2024** |
| Cost of product and services revenue | $2011 | $2221 | $8497 | $8348 |
| Research and development | 11531 | 15587 | 49568 | 66315 |
| Selling, general and administrative | 11672 | 14731 | 50739 | 66086 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total stock-based compensation expense | $25214 | $32539 | $108804 | $140749 |

---

------

![a10x_logoxhorizontalxfullca.jpg](a10x_logoxhorizontalxfullca.jpg)

**10x Genomics, Inc.**

**Consolidated Balance Sheets**

*(Unaudited)*

*(In thousands, except share and per share data)*

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| | **2025** | **2024** |
| **Assets** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $473966 | $344067 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Marketable securities | 49443 | 49335 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 47013 | 87862 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | 56341 | 83107 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other receivables | 35480 | 606 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 22208 | 19410 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 684451 | 584387 |
| Property and equipment, net | 226711 | 252648 |
| Operating lease right-of-use assets | 60450 | 57290 |
| Goodwill | 4511 | 4511 |
| Intangible assets, net | 62329 | 15671 |
| Other noncurrent assets | 2913 | 4129 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $1041365 | $918636 |
| **Liabilities and stockholders' equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $12733 | $12909 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued compensation and related benefits | 42500 | 33615 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 39971 | 41165 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | 23902 | 20658 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | 10985 | 9286 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contingent consideration, current | 23363 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 153454 | 117633 |
| Contingent consideration, noncurrent | 1237 |  |
| Operating lease liabilities, noncurrent | 73376 | 73327 |
| Deferred revenue, noncurrent | 10501 | 12513 |
| Other noncurrent liabilities | 6471 | 5029 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 245039 | 208502 |
| Commitments and contingencies |  |  |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preferred stock, $0.00001 par value; 100,000,000 shares authorized, no shares issued or outstanding as of December 31, 2025 and December 31, 2024 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.00001 par value; 1,100,000,000 shares authorized and 127,691,329 and 122,291,837 shares issued and outstanding as of December 31, 2025 and 2024 | 2 | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 2306690 | 2177672 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (1510591) | (1467047) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income (loss) | 225 | (493) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 796326 | 710134 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $1041365 | $918636 |

---

<br>